Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AA PHASE III, MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 3-ARM PARALLEL GROUP STUDY TO DETERMINE THE EFFICACY AND SAFETY OF LENALIDOMIDE (REVLIMID¿) IN COMBINATION WITH MELPHALAN AND PREDNISONE VERSUS PLACEBO PLUS MELPHALAN AND PREDNISONE IN SUBJECTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA WHO ARE 65 YEARS OF AGE OR OLDER

Next Previous
X
Search
Trial Profile

AA PHASE III, MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 3-ARM PARALLEL GROUP STUDY TO DETERMINE THE EFFICACY AND SAFETY OF LENALIDOMIDE (REVLIMID¿) IN COMBINATION WITH MELPHALAN AND PREDNISONE VERSUS PLACEBO PLUS MELPHALAN AND PREDNISONE IN SUBJECTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA WHO ARE 65 YEARS OF AGE OR OLDER

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 14 Jun 2019

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lenalidomide (Primary) ; Melphalan; Prednisone
  • Indications Multiple myeloma
  • Focus Registrational; Therapeutic Use
  • Sponsors Celgene Corporation; Celgene International SARL

    • Most Recent Events

    • 13 Jun 2019 Trial has been completed in UK.
    • 12 Dec 2017 Results of validation of progression-free survival endpoint by using pooled data from two phase III studies (MM-020 and MM-015) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
    • 27 May 2016 The trial was completed in Greece (end date: 2016-04-13).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top